PATENT CLAIM ANALYSIS

Application Number: 15951658
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "019300"]

Abstract:
Novel peptidomimetic compounds are disclosed, compounds that inhibit protein-protein interactions (PPI) of epidermal growth factor receptors (EGFR), also called human epidermal growth factor receptors (HERs), and that block signaling for cell growth in HER2-overexpressed cancers. The novel peptidomimetics specifically bind the HER2 protein, and thereby inhibit dimerization. The peptidomimetics disrupt both HER2-HER3 and EGFR-HER2 heterodimer formation. The peptidomimetics can be used in the treatment of various types of HER2-overexpressed cancers, including lung, breast, and ovarian cancers.

Claim (Index 3):
The compound of  claim 2 , wherein said compound comprises at least one Arg-[3-amino-3-(1-naphthyl propionic acid)]-Phe-Asp moiety.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.60345
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15310238', '13700915', '11490438', '12157094', '15350801']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7625034813519889
- 35 USC 102 Novelty (BERT): 0.5693400004452038
- Combined Prediction Score: 0.7431871332613105
- Mean Citation Score: 290.384358
- Max Citation Score: 451.3511
- Similarity Product: 352.2924982463657

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test